STOCK TITAN

HyBryte™ Expanded Treatment Results to be Presented at the European Organisation for Research and Treatment of Cancer Conference

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

Soligenix (Nasdaq: SNGX) announced that two lead investigators will present findings from additional supportive trials of HyBryte™ (synthetic hypericin) for treating cutaneous T-cell lymphoma (CTCL) at the European Organisation for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Tumour Group Annual Meeting in Lausanne, Switzerland on October 9-11, 2024.

Dr. Ellen Kim will present a poster with expanded preliminary results from an investigator-initiated study (RW-HPN-MF-01) at the University of Pennsylvania. Dr. Brian Poligone will give an oral presentation on results from two expanded treatment studies (HPN-CTCL-02 and HPN-CTCL-04) conducted at the Rochester Skin Lymphoma Medical Group.

These presentations will elaborate on findings demonstrating the utility of longer treatment times, the lack of significant systemic exposure to hypericin after topical application, and its relative efficacy and tolerability compared to Valchlor®.

Soligenix (Nasdaq: SNGX) ha annunciato che due ricercatori principali presenteranno i risultati di ulteriori studi di supporto su HyBryte™ (ipericina sintetica) per il trattamento del linfoma cutaneo a cellule T (CTCL) durante il Meeting Annuale del Gruppo Tumori Linfoma Cutaneo dell'Organizzazione Europea per la Ricerca e il Trattamento del Cancro (EORTC) che si terrà a Losanna, Svizzera, dal 9 all'11 ottobre 2024.

La Dr.ssa Ellen Kim presenterà un poster con risultati preliminari ampliati di uno studio avviato da investigatori (RW-HPN-MF-01) presso l'Università della Pennsylvania. Il Dr. Brian Poligone terrà una presentazione orale sui risultati di due studi di trattamento ampliati (HPN-CTCL-02 e HPN-CTCL-04) condotti presso il Rochester Skin Lymphoma Medical Group.

Queste presentazioni approfondiranno i risultati che dimostrano l'utilità di tempi di trattamento più lunghi, l'assenza di esposizione sistemica significativa all'ipericina dopo applicazione topica e la sua relativa efficacia e tollerabilità rispetto a Valchlor®.

Soligenix (Nasdaq: SNGX) anunció que dos investigadores principales presentarán hallazgos de ensayos adicionales de apoyo sobre HyBryte™ (hipericina sintética) para el tratamiento del linfoma cutáneo de células T (CTCL) en el Encuentro Anual del Grupo de Tumores Linfoma Cutáneo de la Organización Europea para la Investigación y el Tratamiento del Cáncer (EORTC) en Lausana, Suiza, del 9 al 11 de octubre de 2024.

La Dra. Ellen Kim presentará un póster con resultados preliminares ampliados de un estudio iniciado por investigadores (RW-HPN-MF-01) en la Universidad de Pensilvania. El Dr. Brian Poligone dará una presentación oral sobre los resultados de dos estudios de tratamiento ampliados (HPN-CTCL-02 y HPN-CTCL-04) realizados en el Grupo Médico de Linfoma Cutáneo de Rochester.

Estas presentaciones elaborarán hallazgos que demuestran la utilidad de tiempos de tratamiento más largos, la falta de exposición sistémica significativa a la hipericina tras la aplicación tópica, y su eficacia y tolerabilidad relativa en comparación con Valchlor®.

Soligenix (Nasdaq: SNGX)은 두 명의 주요 연구자가 스위스 로잔에서 2024년 10월 9일에서 11일 사이에 열리는 유럽 암 연구 및 치료기구(EORTC) 피부 림프종 그룹 연례 회의에서 피부 T 세포 림프종(CTCL) 치료를 위한 HyBryte™(합성 하이페리신)의 추가 지원 시험 결과를 발표할 것이라고 발표했습니다.

엘렌 킴 박사는 펜실베이니아 대학교에서 진행된 연구(RW-HPN-MF-01)의 확장된 초기 결과를 담은 포스터를 발표할 예정입니다. 브라이언 폴리곤 박사는 로체스터 피부 림프종 의료 그룹에서 진행된 두 개의 확장 치료 연구(HPN-CTCL-02 및 HPN-CTCL-04)에 대한 구두 발표를 할 것입니다.

이번 발표에서는 더 긴 치료 기간의 유용성, 국소 적용 후 하이페리신에 대한 유의미한 전신 노출의 결여, 그리고 Valchlor®에 비해 상대적인 효능 및 내약성을 보여주는 결과를 자세히 설명할 것입니다.

Soligenix (Nasdaq: SNGX) a annoncé que deux chercheurs principaux présenteront des résultats d'études supplémentaires de soutien sur HyBryte™ (hypericine synthétique) pour le traitement du lymphome à cellules T cutané (CTCL) lors de la Réunion Annuelle du Groupe de Lymphome Cutané de l'Organisation Européenne pour la Recherche et le Traitement du Cancer (EORTC) qui se tiendra à Lausanne, en Suisse, du 9 au 11 octobre 2024.

Dr Ellen Kim présentera un poster avec des résultats préliminaires élargis d'une étude initiée par des chercheurs (RW-HPN-MF-01) à l'Université de Pennsylvanie. Dr Brian Poligone fera une présentation orale sur les résultats de deux études de traitement élargies (HPN-CTCL-02 et HPN-CTCL-04) réalisées au Rochester Skin Lymphoma Medical Group.

Ces présentations approfondiront des résultats démontrant l'utilité de durées de traitement plus longues, l'absence d'exposition systémique significative à l'hypericine après application topique, et son efficacité et sa tolérabilité relatives par rapport à Valchlor®.

Soligenix (Nasdaq: SNGX) gab bekannt, dass zwei leitende Prüfer Ergebnisse aus zusätzlichen unterstützenden Studien zu HyBryte™ (synthetisches Hypericin) zur Behandlung des kutanen T-Zell-Lymphoms (CTCL) beim Jahrestreffen der European Organisation for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Tumour Group in Lausanne, Schweiz, vom 9. bis 11. Oktober 2024 präsentieren werden.

Dr. Ellen Kim wird ein Poster mit erweiterten vorläufigen Ergebnissen aus einer von Prüfern initiierten Studie (RW-HPN-MF-01) an der University of Pennsylvania präsentieren. Dr. Brian Poligone wird einen mündlichen Vortrag über die Ergebnisse von zwei erweiterten Behandlungsstudien (HPN-CTCL-02 und HPN-CTCL-04) halten, die in der Rochester Skin Lymphoma Medical Group durchgeführt wurden.

Diese Präsentationen werden die Ergebnisse vertiefen, die die Nützlichkeit von längeren Behandlungszeiten, das Fehlen einer signifikanten systemischen Exposition gegenüber Hypericin nach topischer Anwendung und die relative Wirksamkeit und Verträglichkeit im Vergleich zu Valchlor® zeigen.

Positive
  • Presentation of expanded treatment results for HyBryte™ at a major cancer research conference
  • Supportive trials demonstrate improved response rates with extended treatment and increased light doses
  • Studies show utility of longer treatment times and lack of significant systemic exposure to hypericin
Negative
  • None.

Two Presentations Highlight HyBryte™ Therapy's Improved Response Rates with Extended Treatment and Increased Light Doses

PRINCETON, N.J., Oct. 7, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that two of its lead investigators are presenting findings from recent additional, supportive trials with HyBryte™ (synthetic hypericin) in the treatment of cutaneous T-cell lymphoma (CTCL). The presentations will occur at the European Organisation for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Tumour Group Annual Meeting in Lausanne, Switzerland on October 9-11, 2024. Dr. Ellen Kim, Director, Penn Cutaneous Lymphoma Program, Vice Chair of Clinical Operations, Dermatology Department, and Professor of Dermatology at the Hospital of the University of Pennsylvania, will present a poster with expanded preliminary results from the investigator-initiated study (RW-HPN-MF-01) she is leading at the University of Pennsylvania. Dr. Brian Poligone, Director of the Rochester Skin Lymphoma Medical Group, will give an oral presentation on recent results from two expanded treatment studies (HPN-CTCL-02 and HPN-CTCL-04) conducted at the Rochester Skin Lymphoma Medical Group.

Oral Presentation:

Session Title: ORAL PRESENTATIONS – CLINICAL STUDIES 1. The official conference program can be found here.

Oral Presentation Title: Phase 2a Study of Topical 0.25% Hypericin in Mycosis Fungoides:
Results and Review of the FLASH Study presented by Brian Poligone, MD, PhD, Director of the Rochester Skin Lymphoma Medical Group on October 9, 2024 at 5:54 pm.          

Poster Presentation:

Topical hypericin ointment photodynamic therapy for early stage mycosis fungoides/CTCL – a Phase 2 real world investigator-initiated study presented on October 9th, 2024 by Ellen Kim, MD, Director, Penn Cutaneous Lymphoma Program, Vice Chair of Clinical Operations, Dermatology Department, and Professor of Dermatology at the Hospital of the University of Pennsylvania.

These presentations further elaborate on the Company's findings in these supportive studies which have demonstrated the utility of longer treatment times (Study RW-HPN-MF-01; investigator-initiated study), the lack of significant systemic exposure to hypericin after topical application (Study HPN-CTCL-02) and its relative efficacy and tolerability compared to Valchlor® (Study HPN-CTCL-04).

About the EORTC CLTG Meeting

An annual meeting of the cutaneous lymphoma tumour group (CLTG), a division of the European Organisation for Research and Treatment of Cancer (EORTC), focuses this year on facilitating the convergence of experts, delegates, and sponsors from Europe and around the globe, all convened to deliberate upon the latest advancements in skin lymphoma as well as the common ground between malignant and benign skin inflammation's research, diagnostics and treatment. The meeting website is available here.

About HyBryte™

HyBryte™ (research name SGX301) is a novel, first-in-class, photodynamic therapy utilizing safe, visible light for activation. The active ingredient in HyBryte™ is synthetic hypericin, a potent photosensitizer that is topically applied to skin lesions that is taken up by the malignant T-cells, and then activated by safe, visible light approximately 24 hours later. The use of visible light in the red-yellow spectrum has the advantage of penetrating more deeply into the skin (much more so than ultraviolet light) and therefore potentially treating deeper skin disease and thicker plaques and lesions. This treatment approach avoids the risk of secondary malignancies (including melanoma) inherent with the frequently employed DNA-damaging drugs and other phototherapy that are dependent on ultraviolet exposure. Combined with photoactivation, hypericin has demonstrated significant anti-proliferative effects on activated normal human lymphoid cells and inhibited growth of malignant T-cells isolated from CTCL patients. In a published Phase 2 clinical study in CTCL, patients experienced a statistically significant (p=0.04) improvement with topical hypericin treatment whereas the placebo was ineffective. HyBryte™ has received orphan drug and fast track designations from the U.S. Food and Drug Administration (FDA), as well as orphan designation from the European Medicines Agency (EMA).

The published Phase 3 FLASH trial enrolled a total of 169 patients (166 evaluable) with Stage IA, IB or IIA CTCL. The trial consisted of three treatment cycles. Treatments were administered twice weekly for the first 6 weeks and treatment response was determined at the end of the 8th week of each cycle. In the first double-blind treatment cycle (Cycle 1), 116 patients received HyBryte™ treatment (0.25% synthetic hypericin) and 50 received placebo treatment of their index lesions. A total of 16% of the patients receiving HyBryte™ achieved at least a 50% reduction in their lesions (graded using a standard measurement of dermatologic lesions, the CAILS score) compared to only 4% of patients in the placebo group at 8 weeks (p=0.04) during the first treatment cycle (primary endpoint). HyBryte™ treatment in this cycle was safe and well tolerated.

In the second open-label treatment cycle (Cycle 2), all patients received HyBryte™ treatment of their index lesions. Evaluation of 155 patients in this cycle (110 receiving 12 weeks of HyBryte™ treatment and 45 receiving 6 weeks of placebo treatment followed by 6 weeks of HyBryte™ treatment), demonstrated that the response rate among the 12-week treatment group was 40% (p<0.0001 vs the placebo treatment rate in Cycle 1). Comparison of the 12-week and 6-week treatment responses also revealed a statistically significant improvement (p<0.0001) between the two timepoints, indicating that continued treatment results in better outcomes. HyBryte™ continued to be safe and well tolerated. Additional analyses also indicated that HyBryte™ is equally effective in treating both plaque (response 42%, p<0.0001 relative to placebo treatment in Cycle 1) and patch (response 37%, p=0.0009 relative to placebo treatment in Cycle 1) lesions of CTCL, a particularly relevant finding given the historical difficulty in treating plaque lesions in particular.

The third (optional) treatment cycle (Cycle 3) was focused on safety and all patients could elect to receive HyBryte™ treatment of all their lesions. Of note, 66% of patients elected to continue with this optional compassionate use / safety cycle of the study. Of the subset of patients that received HyBryte™ throughout all 3 cycles of treatment, 49% of them demonstrated a positive treatment response (p<0.0001 vs patients receiving placebo in Cycle 1). Moreover, in a subset of patients evaluated in this cycle, it was demonstrated that HyBryte™ is not systemically available, consistent with the general safety of this topical product observed to date. At the end of Cycle 3, HyBryte™ continued to be well tolerated despite extended and increased use of the product to treat multiple lesions.

Overall safety of HyBryte™ is a critical attribute of this treatment and was monitored throughout the three treatment cycles (Cycles 1, 2 and 3) and the 6-month follow-up period. HyBryte's™ mechanism of action is not associated with DNA damage, making it a safer alternative than currently available therapies, all of which are associated with significant, and sometimes fatal, side effects. Predominantly these include the risk of melanoma and other malignancies, as well as the risk of significant skin damage and premature skin aging. Currently available treatments are only approved in the context of previous treatment failure with other modalities and there is no approved front-line therapy available. Within this landscape, treatment of CTCL is strongly motivated by the safety risk of each product. HyBryte™ potentially represents the safest available efficacious treatment for CTCL. With very limited systemic absorption, a compound that is not mutagenic and a light source that is not carcinogenic, there is no evidence to date of any potential safety issues.

Following the first Phase 3 study of HyBryte™ for the treatment of CTCL, the FDA and the EMA indicated that they would require a second successful Phase 3 trial to support marketing approval. With agreement from the EMA on the key design components, the second, confirmatory study, called FLASH2, is expected to be initiated before the end of 2024. This study is a randomized, double-blind, placebo-controlled, multicenter study that will enroll approximately 80 subjects with early-stage CTCL. The FLASH2 study replicates the double-blind, placebo-controlled design used in the first successful Phase 3 FLASH study that consisted of three 6-week treatment cycles (18 weeks total), with the primary efficacy assessment occurring at the end of the initial 6-week double-blind, placebo-controlled treatment cycle (Cycle 1). However, this second study extends the double-blind, placebo-controlled assessment to 18 weeks of continuous treatment (no "between-Cycle" treatment breaks) with the primary endpoint assessment occurring at the end of the 18-week timepoint. In the first Phase 3 study, a treatment response of 49% (p<0.0001 vs patients receiving placebo in Cycle 1) was observed in patients completing 18 weeks (3 cycles) of therapy. In this second study, all important clinical study design components remain the same as in the first FLASH study, including the primary endpoint and key inclusion-exclusion criteria. The extended treatment for a continuous 18 weeks in a single cycle is expected to statistically demonstrate HyBryte's™ increased effect over a more prolonged, "real world" treatment course. Given the extensive engagement with the CTCL community, the esteemed Medical Advisory Board and the previous trial experience with this disease, accelerated enrollment in support of this study is anticipated, including the potential to enroll previously identified and treated HyBryte™ patients from the FLASH study. Discussions with the FDA on an appropriate study design remain ongoing. While collaborative, the agency has expressed a preference for a longer duration comparative study over a placebo-controlled trial. Given the shorter time to potential commercial revenue and the similar trial design to the first FLASH study afforded by the EMA accepted protocol, this study is being initiated. At the same time, discussions with the FDA will continue on potential modifications to the development path to adequately address their feedback.

In addition, the FDA awarded an Orphan Products Development grant to support the evaluation of HyBryte™ for expanded treatment in patients with early-stage CTCL, including in the home use setting. The grant, totaling $2.6 million over 4 years, was awarded to the University of Pennsylvania that was a leading enroller in the Phase 3 FLASH study.  Additional supportive  studies have demonstrated the utility of longer treatment times (Study RW-HPN-MF-01), the lack of significant systemic exposure to hypericin after topical application (Study HPN-CTCL-02) and its relative efficacy and tolerability compared to Valchlor® (Study HPN-CTCL-04).

About Cutaneous T-Cell Lymphoma (CTCL)

CTCL is a class of non-Hodgkin's lymphoma (NHL), a type of cancer of the white blood cells that are an integral part of the immune system. Unlike most NHLs which generally involve B-cell lymphocytes (involved in producing antibodies), CTCL is caused by an expansion of malignant T-cell lymphocytes (involved in cell-mediated immunity) normally programmed to migrate to the skin. These malignant cells migrate to the skin where they form various lesions, typically beginning as patches and may progress to raised plaques and tumors. Mortality is related to the stage of CTCL, with median survival generally ranging from about 12 years in the early stages to only 2.5 years when the disease has advanced. There is currently no cure for CTCL. Typically, CTCL lesions are treated and regress but usually return either in the same part of the body or in new areas.

CTCL constitutes a rare group of NHLs, occurring in about 4% of the more than 1.7 million individuals living with the disease in the United States and Europe (European Union and United Kingdom). It is estimated, based upon review of historic published studies and reports and an interpolation of data on the incidence of CTCL that it affects approximately 31,000 individuals in the U.S. (based on SEER data, with approximately 3,200 new cases seen annually) and approximately 38,000 individuals in Europe (based on ECIS prevalence estimates, with approximately 3,800 new cases annually).

About Soligenix

Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Our Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte™ (SGX301 or synthetic hypericin sodium) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). With successful completion of the second Phase 3 study, regulatory approvals will be sought to support potential commercialization worldwide. Development programs in this business segment also include expansion of synthetic hypericin (SGX302) into psoriasis, our first-in-class innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer, and (SGX945) in Behçet's Disease.

Our Public Health Solutions business segment includes development programs for RiVax®, our ricin toxin vaccine candidate, as well as our vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax™, our vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2). The development of our vaccine programs incorporates the use of our proprietary heat stabilization platform technology, known as ThermoVax®. To date, this business segment has been supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases (NIAID), the Defense Threat Reduction Agency (DTRA) and the Biomedical Advanced Research and Development Authority (BARDA).

For further information regarding Soligenix, Inc., please visit the Company's website at https://www.soligenix.com and follow us on LinkedIn and Twitter at @Soligenix_Inc.

This press release may contain forward-looking statements that reflect Soligenix's current expectations about its future results, performance, prospects and opportunities, including but not limited to, potential market sizes, patient populations, clinical trial enrollment, the expected timing for closing the offering described herein and the intended use of proceeds therefrom. Statements that are not historical facts, such as "anticipates," "estimates," "believes," "hopes," "intends," "plans," "expects," "goal," "may," "suggest," "will," "potential," or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual events or results in future periods to differ materially from what is expressed in, or implied by, these statements, and include the expected amount and use of proceeds from the offering and the expected closing date of the offering. Soligenix cannot assure you that it will be able to successfully develop, achieve regulatory approval for or commercialize products based on its technologies, particularly in light of the significant uncertainty inherent in developing therapeutics and vaccines against bioterror threats, conducting preclinical and clinical trials of therapeutics and vaccines, obtaining regulatory approvals and manufacturing therapeutics and vaccines, that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully obtain any further funding to support product development and commercialization efforts, including grants and awards, maintain its existing grants which are subject to performance requirements, enter into any biodefense procurement contracts with the U.S. Government or other countries, that it will be able to compete with larger and better financed competitors in the biotechnology industry, that changes in health care practice, third party reimbursement limitations and Federal and/or state health care reform initiatives will not negatively affect its business, or that the U.S. Congress may not pass any legislation that would provide additional funding for the Project BioShield program. In addition, there can be no assurance as to the timing or success of any of its clinical/preclinical trials. Despite the statistically significant result achieved in the first HyBryte™ (SGX301) Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma, there can be no assurance that the second HyBryte™ (SGX301) Phase 3 clinical trial will be successful or that a marketing authorization from the FDA or EMA will be granted. Additionally, although the EMA has agreed to the key design components of the second HyBryte™ (SGX301) Phase 3 clinical trial, no assurance can be given that the Company will be able to modify the development path to adequately address the FDA's concerns or that the FDA will not require a longer duration comparative study. Notwithstanding the result in the first HyBryte™ (SGX301) Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma and the Phase 2a clinical trial of SGX302 for the treatment of psoriasis, there can be no assurance as to the timing or success of the clinical trials of SGX302 for the treatment of psoriasis. Further, there can be no assurance that RiVax® will qualify for a biodefense Priority Review Voucher (PRV) or that the prior sales of PRVs will be indicative of any potential sales price for a PRV for RiVax®. Also, no assurance can be provided that the Company will receive or continue to receive non-dilutive government funding from grants and contracts that have been or may be awarded or for which the Company will apply in the future. These and other risk factors are described from time to time in filings with the Securities and Exchange Commission (the "SEC"), including, but not limited to, Soligenix's reports on Forms 10-Q and 10-K. Unless required by law, Soligenix assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/hybryte-expanded-treatment-results-to-be-presented-at-the-european-organisation-for-research-and-treatment-of-cancer-conference-302267535.html

SOURCE SOLIGENIX, INC.

FAQ

What is HyBryte™ and what is it used for?

HyBryte™ (synthetic hypericin) is a treatment developed by Soligenix for cutaneous T-cell lymphoma (CTCL), a rare form of skin cancer.

When and where will Soligenix (SNGX) present the HyBryte™ treatment results?

Soligenix will present HyBryte™ treatment results at the European Organisation for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Tumour Group Annual Meeting in Lausanne, Switzerland on October 9-11, 2024.

What are the key findings from the supportive trials of HyBryte™ (SNGX)?

The supportive trials of HyBryte™ demonstrated improved response rates with extended treatment and increased light doses, utility of longer treatment times, lack of significant systemic exposure to hypericin after topical application, and relative efficacy and tolerability compared to Valchlor®.

Who are the lead investigators presenting HyBryte™ results for Soligenix (SNGX)?

Dr. Ellen Kim from the University of Pennsylvania and Dr. Brian Poligone from the Rochester Skin Lymphoma Medical Group are the lead investigators presenting HyBryte™ results for Soligenix.

Soligenix, Inc.

NASDAQ:SNGX

SNGX Rankings

SNGX Latest News

SNGX Stock Data

8.26M
2.28M
0.03%
3.97%
5.89%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
PRINCETON